anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention generally relates to colloidal systems, which may include colloidal particles and/or other types of particles. One aspect of the invention is generally directed to a system comprising fluidic droplets that can be at least partially solidified, e.g., to form colloidal particles. In some embodiments, particles comprising an at least partially solid outer phase encapsulating an inner phase are formed. The inner phase may be any phase, e.g., a solid, a liquid, or a gas. In some cases, solidifying at least a portion of the outer phase of the droplets to form particles may increase the stability of the particles and/or the colloidal system containing the particles. In one set of embodiments, melting or liquefying the outer phase of the particles (for example, by heating the particle to a temperature above a threshold temperature) can allow release of an agent contained within the inner phase, and/or allow the inner phase to coalesce with a phase external to the particles. The melting temperature of the outer phase can be controlled in some embodiments such that the outer phase will melt above a predetermined temperature. In some embodiments, the particles may be formed to be essentially free of an auxiliary stabilizing agent. In some embodiments, an agent may be encapsulated within a particle with relatively high efficiency. Other aspects of the invention are generally directed to methods of making and using such colloidal systems, e.g., containing such particles, kits involving such colloidal systems, or the like.
The Haemonetics 250mL Anticoagulant Citrate Phosphate Double Dextrose (CP2D) and 250mL Additive Solution Formula 3 (AS-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. The anticoagulant solution is metered by the apheresis machine into the collected whole blood. It is not to be infused directly into the donor. After the anticoagulant is used, the bag in which it was contained is discarded. When collecting plasma in the RBCP protocol, the plasma is collected into an empty plasma collection bag. One hundred milliliters (100ml) of AS-3 is transferred into one RBC collection bag when using the RBCP protocol or 2 separate bags when using the 2RBC protocol. AS-3 solution provides nutrients to keep the red blood cells viable for 42 days when refrigerated.

  
CP2D is also indicated for the collection of FFP and PF24 plasma, collected and stored plasma collected using the 822, 822-2P and 822F-2P disposable sets may be frozen within 8 hours (FFP) or within 24 hours which includes 8 hours room temperature storage and 16 hours refrigeration storage (PF24). 

  
The 300mL AS-3 is used in conjunction with automated red blood cell washing devices. AS-3 serves as the nutrient solution for storage of the red blood cell product after deglycerolization. The red blood cells are washed using the Model 215 System. AS-3 is used for priming the disposable and for the last wash of the red blood cells. The washed cells are then re-suspended in 100mL of the AS-3 before transfer into a product collection bag or storage bag. Additive Solution Formula 3 (AS-3) provides nutrients to keep the washed red blood cells viable for up to 14 days after washing when refrigerated. 

  
Neither the CP2D nor the AS-3 container is used for the storage of blood or blood components.
This study investigated Cantonese and Hong Kong Sign Language (HKSL) phonological activation patterns in Hong Kong deaf readers using the ERP technique. Two experiments employing the error disruption paradigm were conducted while recording participants' EEGs. Experiment 1 focused on orthographic and speech-based phonological processing, while Experiment 2 examined sign-phonological processing. ERP analyses focused on the P200 (180-220 ms) and N400 (300-500 ms) components. The results of Experiment 1 showed that hearing readers exhibited both orthographic and phonological effects in the P200 and N400 windows, consistent with previous studies on Chinese reading. In deaf readers, significant speech-based phonological effects were observed in the P200 window, and orthographic effects spanned both the P200 and N400 windows. Comparative analysis between the two groups revealed distinct spatial distributions for orthographic and speech-based phonological ERP effects, which may indicate the engagement of different neural networks during early processing stages. Experiment 2 found evidence of sign-phonological activation in both the P200 and N400 windows among deaf readers, which may reflect the involvement of sign-phonological representations in early lexical access and later semantic integration. Furthermore, exploratory analysis revealed that higher reading fluency in deaf readers correlated with stronger orthographic effects in the P200 window and diminished effects in the N400 window, indicating that efficient orthographic processing during early lexical access is a distinguishing feature of proficient deaf readers.
Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
Calcium acetate acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C4H6CaO4, and its molecular weight is 158.17. Its structural formula is:

Each capsule is of size ‘00el’ hard gelatin capsule shell with blue opaque cap and white opaque body imprinted with “667 mg” on cap and “IG 377” on body in black ink filled with white to off white powder. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium. Each capsule contains the following inactive ingredients: Sodium Lauryl Sulfate and Sodium Stearyl Fumarate. The gelatin cap and body have the following inactive ingredients: FD&C blue #1, FD&C red #3, titanium dioxide, USP, gelatin, USP and iron oxide black.

Calcium acetate capsules are administered orally for the control of hyperphosphatemia in end stage renal failure.

“the drug product meets USP Dissolution Test 4”
NEW MATERIAL:A compound shown by the formula. USE:An intermediate for synthesizing a low toxic novel cysteine-containing physiologically active peptide useful an antiviral agent, cytostatic agent and NK cell enhancer and an intermediate for synthesizing (pro)gamma-interferon, etc. Having improved shelf stability. PREPARATION:For example, a carboxylic acid group of alpha-amino-protecting group-containing amino acid is bonded to a substrate such as polystyrene resin crosslinked with divinyl benzene and the alpha-amino-protecting group is removed. Then, the deprotected free amino group is reacted with a second amino acid. Then, the deprotection and introduction of amino acid are repeated to give the aimed peptide chain and the covalent bond between the carboxylic acid group of carbon-end amino acid of peptide and the resin is cleft. The reaction is preferably carried out under a strongly acidic condition.
At least 60 subjects will be enrolled to ensure 40 (10 adults and 30 babies) completed subjects. The tolerability of this formulation will be monitored in a small group of ten adult subjects with mild to moderate eczema prior to testing in babies. In Group A, adults will be asked to give their informed consent and an evaluation of inclusion/exclusion criteria will be performed at the site. After screening, all subjects will be asked not to use any skin treatments until the next clinic visit. Subjects will use the investigational product as indicated at least twice per day on the face - cheeks only, arms, legs and torso for 14 days. For both adults and babies, only the baseline measurements are collected at 5-10 minutes after first application, but not at Day 1, Day 7 and Day 14 visits. Babies from 6 to 36 months of age with mild to moderate eczema, who meet the eligibility criteria, will follow a similar testing directions in Group B of the study.
The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
Investigating the applying effects of the enhanced recovery after surgery (ERAS) in the perioperative period of elderly lung cancer patients undergoing the surgery. We randomly selected 98 elderly patients with lung cancer who were admitted to our hospital and underwent surgery from January 2022 to September 2023 as study subjects. The control group received conventional care during the perioperative period, and the intervention group received ERAS-guided care measures. The differences in perioperative-related indices, pulmonary function, pain level, inflammatory factors, and postoperative complication rates between these 2 groups were compared. The postoperative extubation time, the activity time since getting out of bad and hospital stay were lower in the observation group than those in the control group (P  < .05). At 3 days postoperatively, the FEV1, forced vital capacity and maximum ventilation volume of these 2 groups were lower than those of their same groups before surgery, and those of the observation group were higher than those of the control group (P  < .05). At 3 days postoperatively, the numerical rating scale in both groups were lower than those of their same groups at 6 hours postoperatively, and the numerical rating scale of the observation group was lower than that of the control group (P  < .05). At 3 days postoperatively, tumor necrosis factor-α, IL-6, and CRP in both groups were higher than those in their same groups before surgery, and those of the observation group was lower than those of the control group (P  < .05). The incidence of postoperative complications in the observation group was lower than that in the control group (P  < .05). ERAS applied in the perioperative period of elderly lung cancer patients undergoing surgery can shorten the hospital stay, promote the postoperative recovery on pulmonary function, alleviate inflammation, and reduce the risk of postoperative complications.
Dupuytren disease is also known as Dupuytren contracture. It is a medical condition characterized by the painless formation of nodules in the palm of the hand. As the disease progresses, approximately 21% - 50% of all patients experience a transformation of these nodules (stage 0/N of Tubiana) into cord-like structures. These cords, in turn, lead to finger contractures (Tubiana stages 1-4) with impairment of hand mobility and stiffening of the palmar skin. The cords are formed on the palmar fascia, a connective tissue sheet in the palm of the hand. This fascia is seen as the vestigial remnant of the palmaris longus tendon. The PLM attaches to the fascia palmaris. A muscle that not everyone has and can therefore be clearly missed. This raises the question of whether the presence of the musculus palmaris longus has any association with the development, recurrence and/or progression of DD and contractures. To investigate a potential predisposition, this study intend to assess the prevalence of the PLM in a group of individuals affected by DD and compare it with a control group (age matched, no signs of DD) without the condition. Interestingly, prior research has already explored this topic. Despite the publication dating back to 1986, it reported a significantly higher occurrence of the palmaris longus tendon in patients affected by DD. Furthermore, a second article from the same year concluded a significant decrease in recurrence when the palmaris longus tendon was resected in combination with regional fasciectomy. Remarkably, no other research on this topic was found despite the promising results of both articles.
Embodiments include a system and method of using biomarkers in the diagnosis of liver disease. A subject can be screened based on expression of specific mRNAs, miRNAs, proteins or peptides in blood, serum or plasma. Specific mRNAs/miRNAs are used as biomarkers to distinguish healthy individuals from individuals affected with a liver disease. Embodiments include 14 mRNA biomarkers to diagnose NAFL vs. healthy liver (i.e. early detection of liver disease). Embodiments also include 9 mRNA biomarkers to diagnose NAFL vs. NASH (i.e. stage of liver disease progression) and 37 mRNA biomarkers to diagnose NASH. Further embodiments include 32 miRNA biomarkers to diagnose and distinguish between NASH, hepatitis B and hepatitis C. Levels of more than one of the mRNAs, miRNAs or proteins can be scored and compared to one or more threshold values to diagnose or determine the prognosis of a liver disease. Embodiments also include a kit for screening healthy subjects from subjects affected with a liver disease.
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gut that cause major life-long disability. Afflicting mostly young people at an age when they are most active both in their private and professional life, inflammatory bowel disease (IBD) represents an important public health problem affecting both the patients education, working abilities, social life . In the past two decades, the incidence and prevalence of CD and UC have been rapidly increasing in Asia. Familial aggregation, twin studies, and recent genetic studies suggest that there is an important genetic component to IBD. In the West, genome wide association (GWA) studies have identified more than 50 genes associated with CD including genes involved in bacterial handling, NOD 2, and the genes involved in autophagy ATG16L1 and IRGM. Only a few of these genes have been studied in Asian populations. Of those which have been studied, such as NOD2, there have been clear differences from Western populations. To date most of the GWA studies have been carried out in cohorts of Caucasian patients. Genetic studies in ethnically different populations may identify new causal variants in IBD, which are likely to lead to further insights into pathophysiology and potential treatments. The aim is to perform a GWA study in Chinese patients with CD and UC. Identifying new genes in Chinese patients will help the investigators to understand the biological pathway and functions in a population in whom the incidence of IBD is increasing. As part of a collaborative project with China, we aim to collect blood samples from 1600 IBD patients and 2000 control subjects in Hong Kong to conduct a GWA study. Samples of 300 IBD patients and 500 controls will be contributed to a collaborative project with China.
Post-operative sore throat (POST) is a common complication of endotracheal intubation. It ranges from 21 to 71.8 %. Various factors contribute to the development of POST, like, female sex, smoking, intubation difficulty and Suxamethonium use, high endotracheal cuff pressure, airway suctioning, long duration of surgery, mucosal injury with laryngoscopy, or pharyngeal airway use and larger size endotracheal tubes \[9\]. POST has also been associated with laryngeal masks, injury with laryngoscopy, or pharyngeal airway use and larger size endotracheal tubes. Basically it is mucosal damage of the throat and trachea which releases inflammatory mediators and produces soreness. POST leads to postoperative dissatisfaction. Patients of POST are uncontended following general anesthesia. Its preemptive amelioration, has been studied using various pharmacological interventions. The list includes, but is not limited to, Benzydamine hydrochloride (BH), aspirin, ketamine, lidocaine and dexamethasone. There is limited evidence based literature available about the incidence of POST in the investigator's locality in the country. The investigators plan to collect data in General OT of Rehman Medical institute (RMI), Peshawar. The city of Peshawar is the largest city of Khyber Pakhtunkhwa, a province of Pakistan, having a population of approximately 2 million. The objectives of our study is to know the magnitude of the problem and ascertain factors associated with postoperative sore throat among patients undergoing elective surgery under general anesthesia with endotracheal intubation.
BACKGROUND: To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by cataract and their proportion of the total number of vision-impaired individuals.
METHODS: A systematic review and meta-analysis of published population studies and gray literature from 2000 to 2020 was carried out to estimate global and regional trends. We developed prevalence estimates based on modeled distance visual impairment and blindness due to cataract, producing location-, year-, age-, and sex-specific estimates of moderate to severe vision impairment (MSVI presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60). Estimates are age-standardized using the GBD standard population.
RESULTS: In 2020, among overall (all ages) 43.3 million blind and 295 million with MSVI, 17.0 million (39.6%) people were blind and 83.5 million (28.3%) had MSVI due to cataract blind 60% female, MSVI 59% female. From 1990 to 2020, the count of persons blind (MSVI) due to cataract increased by 29.7%(93.1%) whereas the age-standardized global prevalence of cataract-related blindness improved by -27.5% and MSVI increased by 7.2%. The contribution of cataract to the age-standardized prevalence of blindness exceeded the global figure only in South Asia (62.9%) and Southeast Asia and Oceania (47.9%).
CONCLUSIONS: The number of people blind and with MSVI due to cataract has risen over the past 30 years, despite a decrease in the age-standardized prevalence of cataract. This indicates that cataract treatment programs have been beneficial, but population growth and aging have outpaced their impact. Growing numbers of cataract blind indicate that more, better-directed, resources are needed to increase global capacity for cataract surgery.
Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms \[mcg\]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication. Patients will self-administer using pre-filled syringes with needle shield or pre-filled pens. Patients with asthma and/or atopic dermatitis will receive a loading dose of 600 mg subcutaneously (followed by 300 mg SC every 2 weeks. Patients with Chronic Rhinosinusitis with Nasal Polyposis will not receive a loading dose and will be treated with 300 mg subcutaneously every 2 weeks. Patients with Eosinophilic Esophagitis will not receive a loading dose of 600 mg subcutaneously and will be treated with 300 mg subcutaneously weekly. Patients who meet criteria for more than one indication will be treated with the higher dose.
PROBLEM TO BE SOLVED: To obtain a composition capable of treating the dermal stains and/or dermal aging by using specific derivatives of rutin and ascorbic acid and setting the pH in the aqueous phase within a specified range. SOLUTION: This composition comprises at least one saccharide ester of rutin and at least one saccharide ester of ascorbic acid at the pH in the aqueous phase regulated within the range of 4-6. Ascorbic acid 2-glucoside is preferred as the saccharide ester of the ascorbic acid and the composition is preferably in the form of an oil-in-water type emulsion or a dispersion of a lipid spherule. The saccharide ester of the ascorbic acid is contained in an amount of 0.01-20wt.% based on the total weight of the composition. The saccharide ester of the rutin is contained in an amount of 0.001-5wt.% based on the total weight of the composition. A hydrophilic or a lipophilic adjuvant may further be contained in the composition.
FIELD: medicine, dermatology, pharmacy. SUBSTANCE: invention relates to application of compound of the formula (I)   where R means group NR 2 R 3  or group OR 4 ; R 1  means methyl group; each of R 2  and R 4  means independently hydrogen atom or C 1-4 -alkyl; R 3  means hydrogen atom, C 1-4 -alkyl or CH 2 OH; X -  is a physiologically acceptable anti-anion. The proposed compound is used for treatment of cutaneous diseases or disorders, hair falling out, solar burns, burns, scalding and for wounds healing. Invention describes pharmaceutical preparations based on compounds of the formula (I) also, in part, for topical application. EFFECT: expanded assortment of preparations used for treatment of cutaneous diseases and disorders. 22 cl
Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
A hemi-tartrate salt of a compound of formula I: Preferably, the tartrate essentially consists of (2R, 3R)-tartrate. The salt preferably has a purity of greater than about 90%, more preferably greater than about 95%, more preferably greater than about 99%. The salt preferably has a melting point of from about 209 to about 213 °C at atmospheric pressure, such as from about 210 to about 212 °C, e.g. about 211 °C. The hemi-tartrate salt of a compound of formula I or a composition thereof is useful in the treatment of hyperglycaemia, or a disorder characterized by hyperglycaemia, preferably wherein the patient is displaying severe insulin resistance. Preferably, the disorder characterised by hyperglycaemia is selected from the group consisting of Type 2 diabetes, Rabson-Mendenhall syndrome, Donohue’s syndrome 15 (leprechaunism), Type A and Type B syndromes of insulin resistance, the HAIR-AN (hyperandrogenism, insulin resistance, and acanthosis nigricans) syndromes, pseudoacromegaly, and lipodystrophy. In another aspect, a process for the preparation of the hemi-tartrate salt of a compound of formula I, comprising reacting a compound of formula (I) with tartaric acid or a solution of tartaric acid, such as wherein the solvent of the solution of tartaric acid is ethanol or an ethanol-water mixture.